Research & Literature

Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.

Virgili G, Menchini F, Casazza G, et al.

The Cochrane database of systematic reviews 2015; (1()):CD008081 doi:10.1002/14651858.CD008081.pub3.

Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema.

Sun JK, Radwan SH, Soliman AZ, et al.

Diabetes 2015; (64(7)):2560-70 doi:10.2337/db14-0782.

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

, Wells JA, Glassman AR, et al.

The New England journal of medicine 2015; (372(13)):1193-203 doi:10.1056/NEJMoa1414264.

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.

Das A, McGuire PG, Rangasamy S

Ophthalmology 2015; (122(7)):1375-94.

Retinal layer location of increased retinal thickness in eyes with subclinical and clinical macular edema in diabetes type 2.

Bandello F, Tejerina AN, Vujosevic S, et al.

Ophthalmic research 2015; (54(3)):112-7 doi:10.1159/000438792.

[Diabetic maculopathy].

Haritoglou C, Kernt M, Wolf A

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2015; (112(10)):871-83; quiz 884-6 doi:10.1007/s00347-015-0127-2.

INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.

Maturi RK, Pollack A, Uy HS, et al.

Retina (Philadelphia, Pa.) 2016; (36(6)):1143-52 doi:10.1097/IAE.0000000000001004.

The Evaluation of Diabetic Macular Ischemia Using Optical Coherence Tomography Angiography.

Bradley PD, Sim DA, Keane PA, et al.

Investigative ophthalmology & visual science 2016; (57(2)):626-31 doi:10.1167/iovs.15-18034.

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Wells JA, Glassman AR, Ayala AR, et al.

Ophthalmology 2016; (123(6)):1351-9.

Diabetic retinopathy.

Wong TY, Cheung CM, Larsen M, et al.

Nature reviews. Disease primers 2016; (2()):16012 doi:10.1038/nrdp.2016.12.

Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.

Payne JF, Wykoff CC, Clark WL, et al.

Ophthalmology 2017; (124(1)):74-81 doi:10.1016/j.ophtha.2016.09.021.

A Revised Approach for the Detection of Sight-Threatening Diabetic Macular Edema.

Litvin TV, Bresnick GH, Cuadros JA, et al.

JAMA ophthalmology 2017; (135(1)):62-68 doi:10.1001/jamaophthalmol.2016.4772.

The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema.

Relhan N, Flynn HW

Current opinion in ophthalmology 2017; (28(3)):205-212 doi:10.1097/ICU.0000000000000362.

Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.

Bressler SB, Beaulieu WT, Glassman AR, et al.

Ophthalmology 2017; (124(4)):431-439 doi:10.1016/j.ophtha.2016.12.005.

Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration.

Strain WD, Cos X, Prünte C

Diabetes research and clinical practice 2017; (126()):1-9 doi:10.1016/j.diabres.2017.01.013.

Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema.

Syed YY

Drugs 2017; (77(5)):575-583 doi:10.1007/s40265-017-0722-4.

Incidence and Progression of Diabetic Retinopathy in Urban India: Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS II), Report 1.

Raman R, Ganesan S, Pal SS, et al.

Ophthalmic epidemiology 2017; (24(5)):294-302 doi:10.1080/09286586.2017.1290257.

Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.

Gale R, Scanlon PH, Evans M, et al.

Eye (London, England) 2017; (31(S1)):S1-S20 doi:10.1038/eye.2017.53.

OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.

Santos AR, Costa MÂ, Schwartz C, et al.

Retina (Philadelphia, Pa.) 2018; (38(6)):1110-1119 doi:10.1097/IAE.0000000000001687.

Fluocinolone acetonide for the treatment of diabetic macular edema.

Veritti D, Sarao V, Diplotti L, et al.

Expert opinion on pharmacotherapy 2017; (18(14)):1507-1516 doi:10.1080/14656566.2017.1363182.

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.

Cai S, Bressler NM

Current opinion in ophthalmology 2017; (28(6)):636-643 doi:10.1097/ICU.0000000000000424.

OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.

Zur D, Iglicki M, Busch C, et al.

Ophthalmology 2018; (125(2)):267-275 doi:10.1016/j.ophtha.2017.08.031.

COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.

Weiss M, Sim DA, Herold T, et al.

Retina (Philadelphia, Pa.) 2018; (38(12)):2293-2300 doi:10.1097/IAE.0000000000001892.

Diabetic Macular Edema: Traditional and Novel Treatment

Tomić M, Vrabec R, Poljičanin T, et al.

Acta clinica Croatica 2017; (56(1)):124-132 doi:10.20471/acc.2017.56.01.18.

Mechanisms of macular edema: Beyond the surface.

Daruich A, Matet A, Moulin A, et al.

Progress in retinal and eye research 2018; (63()):20-68 doi:10.1016/j.preteyeres.2017.10.006.

Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes.

Hsieh YT, Tsai MJ, Tu ST, Hsieh MC

JAMA ophthalmology 2018; (136(1)):68-74 doi:10.1001/jamaophthalmol.2017.5202.

COMPARING FUNDUS FLUORESCEIN ANGIOGRAPHY AND SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE EVALUATION OF DIABETIC MACULAR PERFUSION.

La Mantia A, Kurt RA, Mejor S, et al.

Retina (Philadelphia, Pa.) 2019; (39(5)):926-937 doi:10.1097/IAE.0000000000002045.

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.

Bressler NM, Beaulieu WT, Glassman AR, et al.

JAMA ophthalmology 2018; (136(3)):257-269 doi:10.1001/jamaophthalmol.2017.6565.

Strategies to Improve Prevention and Management in Diabetic Retinopathy: Qualitative Insights from a Mixed-Methods Study.

Beaser RS, Turell WA, Howson A

Diabetes spectrum : a publication of the American Diabetes Association 2018; (31(1)):65-74 doi:10.2337/ds16-0043.

The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey.

Acan D, Calan M, Er D, et al.

BMC ophthalmology 2018; (18(1)):91 doi:10.1186/s12886-018-0753-y.

Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.

Wong TY, Sun J, Kawasaki R, et al.

Ophthalmology 2018; (125(10)):1608-1622 doi:10.1016/j.ophtha.2018.04.007.

Evaluation of a combination digital retinal camera with spectral-domain optical coherence tomography (SD-OCT) that might be used for the screening of diabetic retinopathy with telemedicine: A pilot study.

Sanborn GE, Wroblewski JJ

Journal of diabetes and its complications 2018; (32(11)):1046-1050 doi:10.1016/j.jdiacomp.2018.08.010.

Evaluation of markers of outcome in real-world treatment of diabetic macular edema.

Campos A, Campos EJ, do Carmo A, et al.

Eye and vision (London, England) 2018; (5()):27 doi:10.1186/s40662-018-0119-9.

Diabetic retinopathy

Heitz P, Gaucher D

La Revue du praticien 2017; (67(9)):1001-1008.

Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.

Lee H, Kang KE, Chung H, Kim HC

Japanese journal of ophthalmology 2019; (63(3)):234-242 doi:10.1007/s10384-019-00657-8.

Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.

Wubben TJ, Johnson MW,

American journal of ophthalmology 2019; (204()):13-18 doi:10.1016/j.ajo.2019.03.005.

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.

Baker CW, Glassman AR, Beaulieu WT, et al.

JAMA 2019; (321(19)):1880-1894 doi:10.1001/jama.2019.5790.

Safety of 6000 intravitreal dexamethasone implants.

Rajesh B, Zarranz-Ventura J, Fung AT, et al.

The British journal of ophthalmology 2020; (104(1)):39-46 doi:10.1136/bjophthalmol-2019-313991.

Quantitative Ultra-Widefield Angiographic Features and Associations with Diabetic Macular Edema.

Jiang AC, Srivastava SK, Hu M, et al.

Ophthalmology. Retina 2020; (4(1)):49-56 doi:10.1016/j.oret.2019.08.008.

Impact of Intravitreal Ranibizumab Therapy on Vision Outcomes in Diabetic Macular Edema Patients: A Meta-Analysis.

Falcão M

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 2020; (243(4)):243-254 doi:10.1159/000505070.

Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity.

Zafar S, Smith K, Boland MV, et al.

Current eye research 2020; (45(7)):879-887 doi:10.1080/02713683.2019.1703007.

Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes.

Graue-Hernandez EO, Rivera-De-La-Parra D, Hernandez-Jimenez S, et al.

BMJ open ophthalmology 2020; (5(1)):e000304 doi:10.1136/bmjophth-2019-000304.

Management of diabetic macular edema: experts' consensus in Taiwan.

Chen JT, Chen LJ, Chen SN, et al.

Japanese journal of ophthalmology 2020; (64(3)):235-242 doi:10.1007/s10384-020-00741-4.

The Area and Number of Intraretinal Cystoid Spaces Predict the Visual Outcome after Ranibizumab Monotherapy in Diabetic Macular Edema.

Nagai N, Suzuki M, Uchida A, et al.

Journal of clinical medicine 2020; (9(5)) doi:10.3390/jcm9051391.

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.

Khan M, Aziz AA, Shafi NA, et al.

Cells 2020; (9(8)) doi:10.3390/cells9081869.

Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema.

Markan A, Agarwal A, Arora A, et al.

Therapeutic advances in ophthalmology 2020; (12()):2515841420950513 doi:10.1177/2515841420950513.

Intravitreal steroids for macular edema in diabetes.

Rittiphairoj T, Mir TA, Li T, Virgili G

The Cochrane database of systematic reviews 2020; (11()):CD005656 doi:10.1002/14651858.CD005656.pub3.

Melatonin maintains inner blood-retinal barrier via inhibition of p38/TXNIP/NF-κB pathway in diabetic retinopathy.

Tang L, Zhang C, Yang Q, et al.

Journal of cellular physiology 2021; (236(8)):5848-5864 doi:10.1002/jcp.30269.

Diabetic macular edema.

Ixcamey M, Palma C

Disease-a-month : DM 2021; (67(5)):101138 doi:10.1016/j.disamonth.2021.101138.

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.

Hirano T, Toriyama Y, Takamura Y, et al.

Scientific reports 2021; (11(1)):4488 doi:10.1038/s41598-021-83811-y.

External limiting membrane: retinal structural barrier in diabetic macular edema.

Saxena S, Akduman L, Meyer CH

International journal of retina and vitreous 2021; (7(1)):16 doi:10.1186/s40942-021-00284-x.

Optical Coherence Tomography Biomarkers in Bilateral Diabetic Macular Edema Patients with Asymmetric anti-VEGF Response.

Koc F, Güven YZ, Egrilmez D, Aydın E

Seminars in ophthalmology 2021; (36(5-6)):444-451 doi:10.1080/08820538.2021.1907423.

A Swept source optical coherence tomography angiography study: Imaging artifacts and comparison of non-perfusion areas with fluorescein angiography in diabetic macular edema.

Podkowinski D, Beka S, Mursch-Edlmayr AS, et al.

PloS one 2021; (16(4)):e0249918 doi:10.1371/journal.pone.0249918.

Comparison of Central Macular Fluid Volume With Central Subfield Thickness in Patients With Diabetic Macular Edema Using Optical Coherence Tomography Angiography.

You QS, Tsuboi K, Guo Y, et al.

JAMA ophthalmology 2021; (139(7)):734-741 doi:10.1001/jamaophthalmol.2021.1275.

General health of patients with diabetic macular edema-The LIPSIA study.

Busch C, Katzmann JL, Jochmann C, et al.

PloS one 2021; (16(6)):e0252321 doi:10.1371/journal.pone.0252321.

[Diabetic Macular Edema].

Barth T, Helbig H

Klinische Monatsblatter fur Augenheilkunde 2021; (238(9)):1029-1043 doi:10.1055/a-1545-9656.

[Anti-VEGF therapy for diabetic retinopathy].

Chekhonin ES, Fayzrakhmanov RR, Sukhanova AV, Bosov ED

Vestnik oftalmologii 2021; (137(4)):136-142 doi:10.17116/oftalma2021137041136.

Visual/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year.

Kim JS, Lee S, Kim JY, et al.

Scientific reports 2021; (11(1)):18353 doi:10.1038/s41598-021-97644-2.

PHD2 attenuates high-glucose-induced blood retinal barrier breakdown in human retinal microvascular endothelial cells by regulating the Hif-1α/VEGF pathway.

Li J, Lu X, Wei L, et al.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2022; (71(1)):69-79 doi:10.1007/s00011-021-01518-2.

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen.

Takamura Y, Kida T, Noma H, et al.

Journal of clinical medicine 2021; (10(24)) doi:10.3390/jcm10245738.

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Wykoff CC, Abreu F, Adamis AP, et al.

Lancet (London, England) 2022; (399(10326)):741-755 doi:10.1016/S0140-6736(22)00018-6.

Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.

Garweg JG, Štefanickova J, Hoyng C, et al.

Advances in therapy 2022; (39(6)):2701-2716 doi:10.1007/s12325-022-02119-z.

Interleaved Optical Coherence Tomography: Clinical and Laboratory Biomarkers in Patients with Diabetic Macular Edema.

Suciu CI, Suciu VI, Cuţaş A, Nicoară SD

Journal of personalized medicine 2022; (12(5)) doi:10.3390/jpm12050765.

Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.

Zehden JA, Mortensen XM, Reddy A, Zhang AY

Current diabetes reports 2022; (22(10)):525-536 doi:10.1007/s11892-022-01491-y.

Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy.

Tang L, Xu GT, Zhang JF

Neural regeneration research 2023; (18(5)):976-982 doi:10.4103/1673-5374.355743.

Laser Treatment Modalities for Diabetic Retinopathy.

Pande GS, Tidake P

Cureus 2022; (14(10)):e30024 doi:10.7759/cureus.30024.

Quantification of risk factors for diabetic retinopathy progression.

Tarasewicz D, Conell C, Gilliam LK, Melles RB

Acta diabetologica 2023; (60(3)):363-369 doi:10.1007/s00592-022-02007-6.

OCT outcomes as biomarkers for disease status, visual function, and prognosis in diabetic macular edema.

Velaga SB, Nittala MG, Alagorie AR, et al.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024; (59(2)):109-118 doi:10.1016/j.jcjo.2023.01.012.

Mechanisms of macular edema.

Haydinger CD, Ferreira LB, Williams KA, Smith JR

Frontiers in medicine 2023; (10()):1128811 doi:10.3389/fmed.2023.1128811.

Association Between Contrast Sensitivity and Central Subfield Thickness in Center-Involving Diabetic Macular Edema.

Baldwin G, Vingopoulos F, Zeng R, et al.

Journal of vitreoretinal diseases 2023; (7(3)):232-238 doi:10.1177/24741264231165611.

Pathological Neurovascular Unit Mapping onto Multimodal Imaging in Diabetic Macular Edema.

Murakami T, Ishihara K, Terada N, et al.

Medicina (Kaunas, Lithuania) 2023; (59(5)) doi:10.3390/medicina59050896.

A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment.

Hsieh TC, Deng GH, Chang YC, et al.

Frontiers in endocrinology 2023; (14()):1108097 doi:10.3389/fendo.2023.1108097.

Current Treatments for Diabetic Macular Edema.

Tatsumi T

International journal of molecular sciences 2023; (24(11)) doi:10.3390/ijms24119591.

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.

Debourdeau E, Medard R, Chamard C, et al.

Ophthalmology and therapy 2023; (12(5)):2657-2670 doi:10.1007/s40123-023-00758-1.

Diabetic Macular Edema Is Predictive of Renal Failure in Patients With Diabetes Mellitus and Chronic Kidney Disease.

Ou SH, Chang WC, Wu LY, et al.

The Journal of clinical endocrinology and metabolism 2024; (109(3)):761-770 doi:10.1210/clinem/dgad581.

Optical coherence tomography in the management of diabetic macular oedema.

Szeto SK, Lai TY, Vujosevic S, et al.

Progress in retinal and eye research 2024; (98()):101220 doi:10.1016/j.preteyeres.2023.101220.

[Neovascular Glaucomas - Pathogenesis, Diagnosis, Treatment and Prophylaxis].

Greslechner R, Helbig H

Klinische Monatsblatter fur Augenheilkunde 2023; (240(12)):e55-e71 doi:10.1055/a-2193-2448.

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

Wong TY, Haskova Z, Asik K, et al.

Ophthalmology 2024; (131(6)):708-723 doi:10.1016/j.ophtha.2023.12.026.

Clinical application of optical coherence tomography angiography in diabetic macular edema.

Lv M, Li T, Li Y

African health sciences 2023; (23(2)):484-489 doi:10.4314/ahs.v23i2.56.

Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.

Payne CJ, Gupta U, Maatouk CM, et al.

Eye (London, England) 2024; (38(9)):1687-1693 doi:10.1038/s41433-024-02998-2.

Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group.

Omar A, Williams RG, Whelan J, et al.

Ophthalmology and therapy 2024; (13(5)):1071-1102 doi:10.1007/s40123-024-00923-0.

The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When.

Salvetat ML, Pellegrini F, Spadea L, et al.

Journal of clinical medicine 2024; (13(5)) doi:10.3390/jcm13051327.

Risk factors for diabetic retinopathy, diabetic macular edema, and sight-threatening diabetic retinopathy.

Zhang G, Chen W, Chen H, et al.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2024; (13(3)):100067 doi:10.1016/j.apjo.2024.100067.

Long-term Treatment Patterns for Diabetic Macular Edema: Up to 6-Year Follow-up in the IRIS® Registry.

Kuo BL, Tabano D, Garmo V, et al.

Ophthalmology. Retina 2024; (8(11)):1074-1082 doi:10.1016/j.oret.2024.05.017.

Demographic and Metabolic Risk Factors Associated with Development of Diabetic Macular Edema among Persons with Diabetes Mellitus.

Haliyur R, Marwah S, Mittal S, et al.

Ophthalmology science 2024; (4(6)):100557 doi:10.1016/j.xops.2024.100557.

Systemic Predictors of Diabetic Retinopathy and Diabetic Macular Edema in an Adult Veteran Population.

Tran EM, Gregori NZ, Rachitskaya A, et al.

Clinical ophthalmology (Auckland, N.Z.) 2025; (19()):101-110 doi:10.2147/OPTH.S487047.

Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.

Tahmasebi A, Ebrahimiadib N, Niyousha M, Hassanpoor N

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(10)):2693-2707 doi:10.1007/s00417-025-06878-7.

Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis.

Nanji K, Grad J, Hatamnejad A, et al.

Ophthalmology 2026; (133(1)):75-90 doi:10.1016/j.ophtha.2025.07.038.

Interrelationship of diabetic neuropathy, retinopathy and nephropathy in type 2 diabetes mellitus: a cross-sectional analysis.

Roostaei S, Ashraf A, Fard MV, Johari M

BMC ophthalmology 2025; (25(1)):604 doi:10.1186/s12886-025-04470-5.

Nationwide Analysis of Progressive Kidney Function Decline and Diabetic Macular Edema in Type 2 Diabetes.

Muayad J, Tukur HN, Loya A, et al.

Ophthalmology science 2026; (6(1)):100945 doi:10.1016/j.xops.2025.100945.

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Türkiye: 48-Month Data, BOSPHORUS-DME Study Group Report No. 1.

Özal E, Özkaya A, Arıcı M, et al.

Turkish journal of ophthalmology 2026; (56(1)):31-40 doi:10.4274/tjo.galenos.2026.67863.

Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.

Sacconi R, Scarinci F, Grassi MO, et al.

Ophthalmology and therapy 2026; (15(3)):1033-1055 doi:10.1007/s40123-026-01324-1.

Health, hope and worry: A qualitative study of people with diabetes' experiences with anti-VEGF treatment.

Leksell JK, Granstam E, Granström T, Nerpin E

Diabetic medicine : a journal of the British Diabetic Association 2026; (43(11)):e70334 doi:10.1111/dme.70334.

Disorganization of inner retinal layers and disruption of outer retinal layers as predictors of anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema: A scoping review.

Nadimpalli S, Vijendran S, Bhandary SV

Survey of ophthalmology 2026; (71(6)):1653-1664 doi:10.1016/j.survophthal.2026.05.005.

INFLAMMATORY MEDIATORS IN DIABETIC MACULAR EDEMA: A Prospective, Controlled Study.

Kim SJ, Gangaputra S, Choi L, et al.

Retina (Philadelphia, Pa.) 2026; (46(9)):1513-1519 doi:10.1097/IAE.0000000000004893.

Early visual response provides additional prognostic value beyond baseline OCT features in diabetic macular edema.

Kaplan FB, Tokuç EÖ, Bozkurt E, et al.

European journal of ophthalmology 2026; 11206721261480211 doi:10.1177/11206721261480211.